Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Heart Test Laboratories, Inc. - Common Stock (NQ: HSCS )

3.380 -0.540 (-13.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 37,088
Open 3.890
Bid (Size) 3.300 (2)
Ask (Size) 4.100 (10)
Prev. Close 3.920
Today's Range 3.380 - 4.100
52wk Range 2.360 - 52.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Maison Solutions Shares Are Trading Higher By Around 91%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
-79.78%
-79.78%
1 Month
+21.15%
+21.15%
3 Month
-16.13%
-16.13%
6 Month
-67.02%
-67.02%
1 Year
-91.00%
-91.00%

More News

Read More
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
Recap: Heart Test Laboratories Q3 Earnings
Via Benzinga
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
From Heart Test Laboratories, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
HeartSciences Regains Compliance with Nasdaq Listing Requirements
From Heart Test Laboratories, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
From Heart Test Laboratories, Inc.
Via GlobeNewswire
Why Cracker Barrel Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
US Stocks Edge Higher; Applied Materials Posts Upbeat Earnings
Via Benzinga
Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences to Present at the LD Micro Invitational XIV Conference
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HSCS Stock Earnings: Heart Test Laboratories Beats EPS for Q3 2024
Via InvestorPlace
HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes
From Heart Test Laboratories, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.